



**BlueCross BlueShield
of Oklahoma**

If a conflict arises between a Clinical Payment and Coding Policy (“CPCP”) and any plan document under which a member is entitled to Covered Services, the plan document will govern. If a conflict arises between a CPCP and any provider contract pursuant to which a provider participates in and/or provides Covered Services to eligible member(s) and/or plans, the provider contract will govern. “Plan documents” include, but are not limited to, Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents. BCBSOK may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case. BCBSOK has full and final discretionary authority for their interpretation and application to the extent provided under any applicable plan documents.

Providers are responsible for submission of accurate documentation of services performed. Providers are expected to submit claims for services rendered using valid code combinations from Health Insurance Portability and Accountability Act (“HIPAA”) approved code sets. Claims should be coded appropriately according to industry standard coding guidelines including, but not limited to: Uniform Billing (“UB”) Editor, American Medical Association (“AMA”), Current Procedural Terminology (“CPT®”), CPT® Assistant, Healthcare Common Procedure Coding System (“HCPCS”), ICD-10 CM and PCS, National Drug Codes (“NDC”), Diagnosis Related Group (“DRG”) guidelines, Centers for Medicare and Medicaid Services (“CMS”) National Correct Coding Initiative (“NCCI”) Policy Manual, CCI table edits and other CMS guidelines.

Claims are subject to the code edit protocols for services/procedures billed. Claim submissions are subject to claim review including but not limited to, any terms of benefit coverage, provider contract language, medical policies, clinical payment and coding policies as well as coding software logic. Upon request, the provider is urged to submit any additional documentation.

Prostate Biopsies

Policy Number: CPCPLAB005

Version 1.0

Plan Effective Date: Nov. 1, 2022

Description

BCBSOK has implemented certain lab management reimbursement criteria. Not all requirements apply to each product. Providers are urged to review Plan documents for eligible coverage for services rendered.

Reimbursement Information:

Saturation prostate biopsy or comprehensive 3D (three-dimensional) mapping with biopsy involving 12 core extended sampling (see Note 1 below) **may be reimbursable** in the initial diagnosis of prostate cancer as a follow up to abnormal PSA results, presence of a palpable nodule on digital rectal examination, or suspicious radiologic findings.

Prostate saturation biopsy or comprehensive 3D mapping with biopsy **are not reimbursable** for the diagnosis, staging and management of prostate cancer.

Note 1: One vial per sextant, with no more than two core samples per vial.

Procedure Codes

Codes
0443T, 55700, 55706, 88305, G0416

References:

Ahmed HU, Hu Y, Carter T, et al. Characterizing clinically significant prostate cancer using template prostate mapping biopsy. *J Urol*. Aug 2011; 186(2):458-64. Epub June 15, 2011. PMID 21679984

Ayres BE, Montgomery BS, Barber NJ, et al. The role of transperineal template prostate biopsies in restaging men with prostate cancer managed by active surveillance. *BJU Int*. Apr 2012; 109(8):1170-6. Epub Aug 19, 2011. PMID 21854535

Balducci, L., Pow-Sang, J., Friedland, J., & Diaz, J. I. (1997). Prostate cancer. *Clin Geriatr Med*, 13(2), 283-306. Retrieved from <http://dx.doi.org/>

Barqawi AB, Rove KO, Gholizadeh S, et al. The role of 3-dimensional mapping biopsy in decision making for treatment of apparent early stage prostate cancer. *J Urol*. Jul 2011; 186(1):80-5. Epub May 14, 2011. PMID 21571335

Bekelman, J. E., Rumble, R. B., Chen, R. C., Pisansky, T. M., Finelli, A., Feifer, A., . . . Freedland, S. J. (2018). Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline. *Journal of Clinical Oncology*, 36(32), 3251-3258. doi:10.1200/JCO.18.00606

Bell, K. J., Del Mar, C., Wright, G., Dickinson, J., & Glasziou, P. (2015). Prevalence of incidental prostate cancer: A systematic review of autopsy studies. *Int J Cancer*, 137(7), 1749-1757. doi:10.1002/ijc.29538

Benway, B., Andriole, Gerald. (2021). Prostate biopsy. Retrieved from https://www.uptodate.com/contents/prostate-biopsy?search=prostate%20biopsy&source=search_result&selectedTitle=1~60&usage_type=default&display_rank=1#H3138437049

Bjurlin, M. A., Carroll, P. R., Eggener, S., Fulgham, P. F., Margolis, D. J., Pinto, P. A., . . . Turkbey, B. (2020). Update of the Standard Operating Procedure on the Use of Multiparametric Magnetic Resonance Imaging for the Diagnosis, Staging and Management of Prostate Cancer. *J Urol*, 203(4), 706-712. doi:10.1097/ju.0000000000000617

Brown, L. C., Ahmed, H. U., Faria, R., El-Shater Bosaily, A., Gabe, R., Kaplan, R. S., . . . Emberton, M. (2018). Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study. *Health Technol Assess*, 22(39), 1-176. doi:10.3310/hta22390

Coakley, F. V., Oto, A., Alexander, L. F., Allen, B. C., Davis, B. J., Froemming, A. T., . . . Eberhardt, S. C. (2017). ACR Appropriateness Criteria((R)) Prostate Cancer-Pretreatment Detection, Surveillance, and Staging. *J Am Coll Radiol*, 14(5s), S245-S257. doi:10.1016/j.jacr.2017.02.026

EAU. (2021). Prostate Cancer. Retrieved from <https://uroweb.org/guideline/prostate-cancer/#5>

Eichler, K., Hempel, S., Wilby, J., Myers, L., Bachmann, L. M., & Kleijnen, J. (2006). Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. *J Urol*, 175(5), 1605-1612. doi:10.1016/s0022-5347(05)00957-2

Gosselaar, C., Roobol, M. J., Roemeling, S., Wolters, T., van Leenders, G. J., & Schroder, F. H. (2008). The value of an additional hypoechoic lesion-directed biopsy core for detecting prostate cancer. *BJU Int*, 101(6), 685-690. doi:10.1111/j.1464-410X.2007.07309.x

Grummet JP, Weerakoon M, Huang S, et al. Sepsis and 'superbugs': should we favor the transperineal over the transrectal approach for prostate biopsy? *BJU Int*. Sep 2014; 114(3):384-8. Epub Feb 19, 2014. PMID 24612341

Hodge, K. K., McNeal, J. E., Terris, M. K., & Stamey, T. A. (1989). Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. *J Urol*, 142(1), 71-74; discussion 74-75. Retrieved from <http://dx.doi.org/>

Hoffman, R. (2020). Screening for prostate cancer – UpToDate. Retrieved from https://www.uptodate.com/contents/screening-for-prostate-cancer?source=see_link#H30

Kantoff, P., Taplin, M.-E., & Smith, J. (2018). Clinical presentation and diagnosis of prostate cancer - UpToDate. In M. Ross (Ed.), *UpToDate*. Retrieved from https://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-prostate-cancer?source=search_result&search=prostate%20cancer&selectedTitle=2~150#H74636058

Kantoff, P., Taplin, M.-E., & Smith, J. (2020). Clinical presentation and diagnosis of prostate cancer - UpToDate. Retrieved from https://www.uptodate.com/contents/clinical-presentation-and-diagnosis-of-prostate-cancer?source=search_result&search=prostate%20cancer&selectedTitle=2~150#H74636058

Klotz, L., Chin, J., Black, P. C., Finelli, A., Anidjar, M., Bladou, F., . . . Haider, M. A. (2021). Comparison of Multiparametric Magnetic Resonance Imaging-Targeted Biopsy With Systematic Transrectal Ultrasonography Biopsy for Biopsy-Naive Men at Risk for Prostate Cancer: A Phase 3 Randomized Clinical Trial. *JAMA Oncol*, 7(4), 534-542. doi:10.1001/jamaoncol.2020.7589

Moran BJ, Braccioforte MH, Conterato DJ. Re-biopsy of the prostate using stereotactic transperineal technique. *J Urol*. Oct 2006; 176:1376-81. PMID 16952636

Nafie S, Pal RP, Dormer JP, et al. Transperineal template prostate biopsies in men with raised PSA despite two previous sets of negative TRUS-guided prostate biopsies. *World J Urol*. Aug 2014; 32(4):971-5. Epub Dec 14, 2013. PMID 24337167

Nam RK, Saskin R, Lee Y, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. *J Urol*. Jan 2013; 189(1Suppl); S12-7; discussion S17-8. PMID 23234616

NCCN. (2021a). NCCN Clinical Practice Guidelines in Oncology; Prostate Cancer. v2. Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

NCCN. (2021b). NCCN Clinical Practice Guidelines in Oncology; Prostate Cancer Early Detection. v2. Retrieved from https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf

Numao N, Kawakami S, Sakura M, et al. Characteristics and clinical significance of prostate cancers missed by initial transrectal 12-core biopsy. *BJU Int.* Mar 2012; 109(5):665-71. Epub Sep 21, 2011. PMID 21939488

Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., . . . Gillessen, S. (2020). Prostate Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology*. doi:10.1016/j.annonc.2020.06.011

Pepe, P., & Aragona, F. (2007). Saturation prostate needle biopsy and prostate cancer detection at initial and repeat evaluation. *Urology*, 70(6), 1131-1135. doi:10.1016/j.urology.2007.07.068

Pepe P, Aragona F. Prostate biopsy: results and advantages of the transperineal approach—twenty-year experience of a single center. *World J Urol.* Apr 2014; 32 92 0; 373-7. Epub Jun 7, 2013. PMID 23743734

Pepe, P., Garufi, A., Priolo, G. D., Galia, A., Fraggetta, F., & Pennisi, M. (2018). Is it Time to Perform Only Magnetic Resonance Imaging Targeted Cores? Our Experience with 1,032 Men Who Underwent Prostate Biopsy. *J Urol*, 200(4), 774-778. doi:10.1016/j.juro.2018.04.061

Pepe, P., Pennisi, M., & Fraggetta, F. (2020). How Many Cores Should be Obtained During Saturation Biopsy in the Era of Multiparametric Magnetic Resonance? Experience in 875 Patients Submitted to Repeat Prostate Biopsy. *Urology*, 137, 133-137. doi:10.1016/j.urology.2019.11.016

Samir S. Taneja, M. C., Marc A. Bjurlin, DO, H. Ballentine Carter, MD, Michael S. Cookson, MD, MMHC, Leonard G. Gomella, MD, FACS, David F. Penson, MD, MPH, Paul Schellhammer, MD, Steven Schlossberg MD, MBA, Dean Troyer, MD,. (2015). American Urological Association - Optimal Techniques of Prostate Biopsy and Specimen Handling. Retrieved from <http://www.auanet.org/guidelines/prostate-biopsy-and-specimen-handling>.

Sanda, M. G., Cadeddu, J. A., Kirkby, E., Chen, R. C., Crispino, T., Fontanarosa, J., . . . Treadwell, J. R. (2017). Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options. *J Urol*. doi:10.1016/j.juro.2017.11.095

Sidana, A., Watson, M. J., George, A. K., Rastinehad, A. R., Vourganti, S., Rais-Bahrami, S., . . . Pinto, P. A. (2018). Fusion prostate biopsy outperforms 12-core systematic prostate biopsy in patients with prior negative systematic biopsy: A multi-institutional analysis. *Urol Oncol*, 36(7), 341.e341-341.e347. doi:10.1016/j.urolonc.2018.04.002

Siegel, R. L., Miller, K. D., & Jemal, A. (2019). Cancer statistics, 2019. *CA: A Cancer Journal for Clinicians*, 69(1), 7-34. doi:10.3322/caac.21551

Smith, R. A., Andrews, K. S., Brooks, D., Fedewa, S. A., Manassaram-Baptiste, D., Saslow, D., . . . Wender, R. C. (2018). Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. *CA: A Cancer Journal for Clinicians*, 68(4), 297-316. doi:10.3322/caac.21446

Smith, R. A., Andrews, K. S., Brooks, D., Fedewa, S. A., Manassaram-Baptiste, D., Saslow, D., & Wender, R. C. (2019). Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. *CA: A Cancer Journal for Clinicians*, 69(3), 184-210. doi:10.3322/caac.21557

Tabayoyong, W., & Abouassaly, R. (2015). Prostate Cancer Screening and the Associated Controversy. *Surg Clin North Am*, 95(5), 1023-1039. doi:10.1016/j.suc.2015.05.001

Taira AV, Merrick GS, Galbreath RW, et al. Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. *Prostate Cancer Prostatic Dis*. Mar 2010; 13(1):71-7. Sep 29, 2009. PMID 19786982

Thompson, J. E., Hayen, A., Landau, A., Haynes, A. M., Kalapara, A., Ischia, J., . . . Stricker, P. D. (2015). Medium-term oncological outcomes for extended vs saturation biopsy and transrectal vs transperineal biopsy in active surveillance for prostate cancer. *BJU Int*, 115(6), 884-891. doi:10.1111/bju.12858

USPSTF. (2018). Screening for prostate cancer: US Preventive Services Task Force recommendation statement. *JAMA*, 319(18), 1901-1913. doi:10.1001/jama.2018.3710

Wolf, A. M., Wender, R. C., Etzioni, R. B., Thompson, I. M., D'Amico, A. V., Volk, R. J., . . . Smith, R. A. (2010). American Cancer Society guideline for the early detection of prostate cancer: update 2010. *CA Cancer J Clin*, 60(2), 70-98. doi:10.3322/caac.20066

Zaytoun, O. M., Moussa, A. S., Gao, T., Fareed, K., & Jones, J. S. (2011). Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population. *J Urol*, 186(3), 850-854. doi:10.1016/j.juro.2011.04.069

Policy Update History:

11/1/2022	New policy
-----------	------------